Chronic rhinosinusitis with nasal polyps (CRSwNP) inflammatory endotypes are associated with long-term air pollutant and allergen exposure.

Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in ...

USA: In a recent exposure-matched study, researchers found that long-term exposure to fine particulate matter (PM2.5) may ...

We are pleased to accelerate our guidance on several near-term events, including the top-line data readout from our Phase 2 clinical trial of verekitug in patients with CRSwNP, expected in the thi ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

GSK to present data from across its respiratory portfolio at 2025 ATS International Congress in San Francisco: London, UK Monday, May 5, 2025, 10:00 Hrs [IST] GSK plc announced da ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

Amgen today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...